☆ 4.6 Article

Identification of novel BRD4 inhibitors by pharmacophore screening, molecular docking, and molecular dynamics simulation

JOURNAL OF MOLECULAR STRUCTURE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Medicinal

A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes

Huarui Cui et al.

Summary: Chemical probes for epigenetic proteins are crucial for understanding gene regulation and therapeutic development. In this study, a structure-activity relationship analysis led to the discovery of selective small molecule inhibitors for the BRD4 N-terminal bromodomain, providing new design rules for selective inhibitors of individual BET bromodomain.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Chemistry, Physical

Identification of potent CypD inhibitors via pharmacophore based virtual screening, docking and molecular dynamics simulation

Xiao-Zhong Chen et al.

Summary: This study identified novel potential CypD inhibitors through screening of the ZINC database and molecular docking, providing a basis for the treatment of acute pancreatitis.

JOURNAL OF MOLECULAR STRUCTURE (2022)

添加到收藏夹

Article Chemistry, Physical

Structural-based virtual screening and identification of novel potent antimicrobial compounds against YsxC of Staphylococcus aureus

Reena Kumari et al.

Summary: In this study, a 3-dimensional model of Ribosome biogenesis GTP-binding (YsxC) was built, and potent molecules against Staphylococcus aureus were identified. Molecular docking analysis revealed that the screened molecules had higher binding affinity than GTP. Molecular dynamics analysis confirmed the stability of YsxC-inhibitor(s) complexes. The findings provide valuable insights for designing novel compounds against S. aureus.

JOURNAL OF MOLECULAR STRUCTURE (2022)

添加到收藏夹

Article Chemistry, Physical

Identification of novel dual inhibitors targeting XOR and URAT1 via multiple virtual screening methods

XinYing Zhu et al.

Summary: This study aimed to find compounds with dual XOR and URAT1 inhibitory activity to address the issue of insufficient potency by single-target drugs. Multiple computational methods were used to screen and evaluate potential dual inhibitors.

JOURNAL OF MOLECULAR STRUCTURE (2022)

添加到收藏夹

Article Chemistry, Physical

In-silico studies for the development of novel RET inhibitors for cancer treatment

Sushanta Bhattacharya et al.

Summary: The study investigated potential compounds for RET inhibition using pharmacophore modeling and 3D-QSAR analysis. Through virtual screening and docking methodologies, four hit compounds with promising docking scores were identified, showing excellent pharmacokinetic profiles. The results may aid researchers in developing novel RET inhibitors with improved therapeutic efficacy for cancer treatment.

JOURNAL OF MOLECULAR STRUCTURE (2022)

添加到收藏夹

Article Chemistry, Physical

Pharmacophore modeling, virtual screening, molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach

Gurubasavaraja Swamy Purwarga Matada et al.

Summary: Breast cancer is the leading cause of death in women worldwide. In this study, we identified three potential compounds with good binding affinity to HER2, a protein associated with breast cancer. These compounds showed key residue interactions and stable molecular interactions in in-silico studies, suggesting their potential for further optimization and drug development.

JOURNAL OF MOLECULAR STRUCTURE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis

Zhangxu He et al.

Summary: Bromodomain containing protein 4 (BRD4) is an epigenetic reader that has emerged as a potential therapeutic target for various diseases. Through high-throughput virtual screening and structure-activity relationship studies, a series of novel compounds targeting BRD4 were developed. Among them, compound C-34 showed better pharmacokinetic and physicochemical properties and exhibited lower cytotoxicity in vitro and in vivo, confirming its potential as a therapeutic agent for fibrotic cardiovascular disease.

ACTA PHARMACEUTICA SINICA B (2022)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

Jingjing Chen et al.

Summary: Selective HDAC/BRD4 dual inhibitors were designed and synthesized using pharmacophore fusion strategy, leading to the identification of three types of inhibitors with different cellular activities. Among them, the selective dual inhibitor 41c showed synergistic effects in inducing cell cycle arrest and apoptosis in MV-4-11 cells. This study supports the use of selective HDAC/BRD4 dual inhibitors as epigenetic probes for future biological evaluation in various cancer cell lines.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Physical

Identification of anti-mycobacterial agents against mmpL3: Virtual screening, ADMET analysis and MD simulations

Kaushikkumar A. Bhakhar et al.

Summary: Tuberculosis is one of the top 10 causes of communicable disease deaths worldwide, and the mmpL3 target protein plays a crucial role in synthesizing essential components of the mycobacterial outer membrane. The search for new anti-tubercular agents through computational chemistry has provided a promising start in the field of molecular modeling for mmpL3 inhibitors.

JOURNAL OF MOLECULAR STRUCTURE (2021)

添加到收藏夹

Article Chemistry, Physical

Semi-automated Optimization of the CHARMM36 Lipid Force Field to Include Explicit Treatment of Long-Range Dispersion

Yalun Yu et al.

Summary: The development of the CHARMM lipid force field has a long history, with the current version being CHARMM36 (C36). This work introduces a semi-automated approach to reparametrize the CHARMM lipid force field with consistent inclusion of long-range dispersion through the Lennard-Jones particle-mesh Ewald method. With careful selection of target properties and reweighting settings, the newly optimized lipid force field, denoted as C36/LJ-PME, successfully incorporates the explicit treatment of long-range dispersion.

JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2021)

添加到收藏夹

Article Oncology

Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects

Young Hun Kim et al.

Summary: The study introduced a novel chemical scaffold that effectively suppressed brd4 activity, exhibiting cytotoxic effects against various cancer cells both in vitro and in vivo.

ONCOLOGY LETTERS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia

Ziying Feng et al.

Summary: Compound 58 has been identified as a novel BRD4 inhibitor with potent inhibitory effects on leukemia cell proliferation, potentially mediated through the down-regulation of the oncogene c-myc. In vivo pharmacokinetics studies showed favorable PK features compared to (+)-JQ1, indicating its potential for further development as a leukemia inhibitor.

BIOORGANIC CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design

Ashvinikumar Gavai et al.

Summary: Inhibition of BET proteins is an attractive strategy for targeting oncogenes like cMYC. Through a combination of structure-activity relationship and protein structure-guided drug design, the compound BMS-986158 with excellent binding potency was discovered and selected for clinical evaluation based on its favorable in vivo activity in hematologic and solid tumor models.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Physical

In silico strategy for isoform-selective 5-HT2AR and 5-HT2CR inhibitors

Xiaohui Geng et al.

Summary: 5-HT2AR and 5-HT2CR, widely expressed in the brain, are important targets for antipsychotic and addiction medications, as well as depression and addiction treatments. Analysis of their structure and chemical properties revealed key residues contributing to selectivity, providing insights for designing selective inhibitors.

MOLECULAR SYSTEMS DESIGN & ENGINEERING (2021)

添加到收藏夹

Review Genetics & Heredity

Cancer's epigenetic drugs: where are they in the cancer medicines?

Sorayya Ghasemi

PHARMACOGENOMICS JOURNAL (2020)

添加到收藏夹

Article Chemistry, Medicinal

Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors

Ning-Yu Wang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Review Chemistry, Medicinal

Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery

Dailin Liang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Identification of xanthine oxidase inhibitors through hierarchical virtual screening

Ying Yang et al.

RSC ADVANCES (2020)

添加到收藏夹

Article Biology

Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations

Xiao-Yan Feng et al.

COMPUTATIONAL BIOLOGY AND CHEMISTRY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors

Xiangyang Li et al.

CHEMMEDCHEM (2018)

添加到收藏夹

Article Chemistry, Medicinal

Design, synthesis and biological evaluation of benzo[cd]indo1-2(1H)-ones derivatives as BRD4 inhibitors

Yuxin Feng et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4

Xin Jin et al.

MOLECULAR CELL (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting Brd4 for cancer therapy: inhibitors and degraders

Yingchao Duan et al.

MEDCHEMCOMM (2018)

添加到收藏夹

Article Oncology

NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells

Kotaro Hishiki et al.

LEUKEMIA RESEARCH (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Bromodomain inhibitors and cancer therapy: From structures to applications

Montserrat Perez-Salvia et al.

EPIGENETICS (2017)

添加到收藏夹

Article Toxicology

Molecular docking reveals the potential of phthalate esters to inhibit the enzymes of the glucocorticoid biosynthesis pathway

Shahzad Ahmad et al.

JOURNAL OF APPLIED TOXICOLOGY (2017)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor

Jianping Hu et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Chemistry, Medicinal

Drug Discovery Targeting Bromodomain-Containing Protein 4

Zhiqing Liu et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Keith F. McDaniel et al.

JOURNAL OF MEDICINAL CHEMISTRY (2017)

添加到收藏夹

Article Chemistry, Multidisciplinary

Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations

Bryce K. Allen et al.

ACS OMEGA (2017)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays

Zhongya Sun et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains

Alexander M. Taylor et al.

ACS MEDICINAL CHEMISTRY LETTERS (2016)

添加到收藏夹

Review Chemistry, Medicinal

An Overview on Small Molecule Inhibitors of BRD4

Wenhai Huang et al.

MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

Philipp Rathert et al.

NATURE (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors

Stuart W. J. Ember et al.

ACS CHEMICAL BIOLOGY (2014)

添加到收藏夹

Article Chemistry, Medicinal

g_mmpbsa-A GROMACS Tool for High-Throughput MM-PBSA Calculations

Rashmi Kumari et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition

Junwei Shi et al.

MOLECULAR CELL (2014)

添加到收藏夹

Article Oncology

PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains

Sarah Picaud et al.

CANCER RESEARCH (2013)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

Olivier Mirguet et al.

JOURNAL OF MEDICINAL CHEMISTRY (2013)

添加到收藏夹

Article Chemistry, Medicinal

Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain

Lele Zhao et al.

JOURNAL OF MEDICINAL CHEMISTRY (2013)

添加到收藏夹

Article Chemistry, Medicinal

Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)

Jonathan Seal et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

Panagis Filippakopoulos et al.

CELL (2012)

添加到收藏夹

Review Pharmacology & Pharmacy

Place your BETs: the therapeutic potential of bromodomains

R. K. Prinjha et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2012)

添加到收藏夹

Review Oncology

BET domain co-regulators in obesity, inflammation and cancer

Anna C. Belkina et al.

NATURE REVIEWS CANCER (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation

Sergei Nechaev et al.

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2011)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and Characterizatlion of Small Molecule Inhibitors of the BET Family Bromodomains

Chun-wa Chung et al.

JOURNAL OF MEDICINAL CHEMISTRY (2011)

添加到收藏夹

Article Biochemical Research Methods

Generation and validation of the first predictive pharmacophore model for cyclin-dependent kinase 9 inhibitors

Cheng Fang et al.

JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Mark A. Dawson et al.

NATURE (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes

Janine M. Lamonica et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Selective inhibition of BET bromodomains

Panagis Filippakopoulos et al.

NATURE (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design

Yingda Ye et al.

NEUROCHEMISTRY INTERNATIONAL (2010)

添加到收藏夹

Article Chemistry, Physical

GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation

Berk Hess et al.

JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2008)

添加到收藏夹

Article Cell Biology

Brd2 is a TBP-associated protein and recruits TBP into E2F-1 transcriptional complex in response to serum stimulation

Jinhong Peng et al.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2007)

添加到收藏夹

Article Chemistry, Medicinal

Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening

TA Halgren et al.

JOURNAL OF MEDICINAL CHEMISTRY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.